Loading the security overview…
Where the tokens are
Trade LLY perps| Quarter | Reported | EPS | EPS vs year ago | Revenue | Revenue vs year ago | Consensus EPS |
|---|---|---|---|---|---|---|
| Q2 FY26ended Jun 30, 2026 | Aug 6, 2026 | $7.94 | +26.2% | $22.97B | +47.7% | $8.65 |
| Q1 FY26ended Mar 31, 2026 | May 7, 2026 | $8.26 | +169.9% | $19.80B | +55.5% | $7.35 |
| Q4 FY25ended Dec 31, 2025 | — | $7.39 | +51.4% | $19.29B | +42.6% | — |
| Q3 FY25ended Sep 30, 2025 | — | $6.21 | +480.4% | $17.60B | +53.9% | — |
| Q2 FY25ended Jun 30, 2025 | — | $6.29 | +91.8% | $15.56B | +37.6% | — |
| Q1 FY25ended Mar 31, 2025 | — | $3.06 | +23.4% | $12.73B | +45.2% | — |
| Q4 FY24ended Dec 31, 2024 | — | $4.88 | +102.5% | $13.53B | +44.7% | — |
| Q3 FY24ended Sep 30, 2024 | — | $1.07 | — | $11.44B | +20.4% |
Growth compares each quarter with the same fiscal quarter a year earlier, and is left blank where that quarter is missing or its figure was zero or a loss. Consensus is the estimate published before each report. It usually refers to adjusted EPS, so it is shown beside the GAAP figure rather than subtracted from it: the difference would not be a beat or a miss.
Figures describe Eli Lilly shares, not any token. As of Aug 6, 2026, from Massive's standardised financials and the earnings calendar.
| — |
| Q2 FY24ended Jun 30, 2024 | — | $3.28 | — | $11.30B | — | — |
| Q1 FY24ended Mar 31, 2024 | — | $2.48 | — | $8.77B | — | — |
| Q4 FY23ended Dec 31, 2023 | — | $2.41 | — | $9.35B | — | — |
| Q3 FY23ended Sep 30, 2023 | — | −$0.06 | — | $9.50B | — | — |